+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Somatostatin Receptor Type 4 (SSTR4) - Drugs In Development, 2021

  • ID: 5359600
  • Drug Pipelines
  • June 2021
  • Region: Global
  • 41 pages
  • Global Markets Direct

FEATURED COMPANIES

  • Eli Lilly and Co
  • GlyTech Inc
  • Peptide Logic LLC
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

Somatostatin Receptor Type 4 (SSTR4) pipeline Target constitutes close to 5 molecules. The latest report Somatostatin Receptor Type 4 - Drugs In Development, 2021, outlays comprehensive information on the Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Somatostatin Receptor Type 4 (SSTR4) - Somatostatin receptor type 4 is a protein encoded by the SSTR4 gene. The activity of receptor is mediated by G proteins which inhibits adenylyl cyclase. It mediates antiproliferative action of somatostatin in tumor cells. It is functionally coupled to inhibition of adenylate cyclase and activation of both arachidonate release and mitogen-activated protein (MAP) kinase cascade. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 2, 1 and 2 respectively. Report covers products from therapy areas Hormonal Disorders, Central Nervous System, Metabolic Disorders and Oncology which include indications Acromegaly, Diabetic Neuropathic Pain, Low Back Pain, Neuroendocrine Tumors, Osteoarthritis Pain, Pain and Pituitary ACTH Hypersecretion (Cushing Disease).

Furthermore, this report also reviews key players involved in Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Somatostatin Receptor Type 4 (SSTR4)
  • The report reviews Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics
Reasons to Buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Somatostatin Receptor Type 4 (SSTR4) Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Somatostatin Receptor Type 4 (SSTR4) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Eli Lilly and Co
  • GlyTech Inc
  • Peptide Logic LLC
Introduction
  • Report Coverage
Somatostatin Receptor Type 4 (SSTR4) - Overview

Somatostatin Receptor Type 4 (SSTR4) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
Somatostatin Receptor Type 4 (SSTR4) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
Somatostatin Receptor Type 4 (SSTR4) - Companies Involved in Therapeutics Development
  • Eli Lilly and Co
  • GlyTech Inc
  • Peptide Logic LLC
  • Strongbridge Biopharma plc
Somatostatin Receptor Type 4 (SSTR4) - Drug Profiles

GT-02037- - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
LY-3556050 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Monoclonal Antibody Conjugate to Agonize SSTR4 for Pain - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
veldoreotide ER - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
veldoreotide IR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Somatostatin Receptor Type 4 (SSTR4) - Dormant Products

Somatostatin Receptor Type 4 (SSTR4) - Product Development Milestones

Featured News & Press Releases
  • Jul 18, 2017: Centrexion Provides Pipeline Updates, Plans for Phase 2 Study of Pain Drug Candidate CNTX-0290
  • May 31, 2016: Strongbridge Biopharma plc Announces Presentation of COR-005 Data at the European Congress of Endocrinology
  • Apr 22, 2014: Aspireo Reports Data in Further Phase Ib Study
  • Sep 25, 2013: FDA Grants Orphan Drug Designation for Aspireo’s Somatoprim
  • Jun 18, 2013: Aspireo Reports Start of Further Phase I Study in Healthy Volunteers
  • Apr 03, 2013: Aspireo Pharma Reports Somatoprim Phase IIa Proof Of Concept Results In Acromegaly
  • Jan 07, 2013: Aspireo Pharma Reports Phase Ib Interim Data For Somatoprim
  • Nov 26, 2012: Aspireo Pharma Announces EMA's Committee For Orphan Medicinal Products Recommends Orphan Medicinal Product Designation For Somatoprim
  • Nov 06, 2012: Aspireo Pharma Starts Somatoprim Phase IIa Study In Acromegaly Patients
  • Sep 28, 2012: Evotec And Aspireo Pharma Enter Into Strategic Advisory Agreement For Somatoprim
  • Jun 26, 2012: Somatoprim is a potent agonist of Somatostatin Receptors 2 and 5
  • Apr 05, 2012: Aspireo Starts Phase I Multi Ascending Dose Study with Somatoprim
  • Feb 26, 2009: DeveloGen Reports Positive Phase I Clinical Trial Results for DG3173
  • Oct 08, 2008: DeveloGen Announces Completion Of A Phase I Clinical Trial Of DG3173, A Novel Somatostatin Analogue For The Treatment Of Acromegaly
Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Indication, 2021
  • Number of Products under Development by Companies, 2021
  • Products under Development by Companies, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Pipeline by Eli Lilly and Co, 2021
  • Pipeline by GlyTech Inc, 2021
  • Pipeline by Peptide Logic LLC, 2021
  • Pipeline by Strongbridge Biopharma plc, 2021
  • Dormant Products, 2021
List of Figures
  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Top 10 Indications, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021
Note: Product cover images may vary from those shown
  • Eli Lilly and Co
  • GlyTech Inc
  • Peptide Logic LLC
  • Strongbridge Biopharma plc
Note: Product cover images may vary from those shown
Adroll
adroll